BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 18039098)

  • 1. Neurofibromatosis.
    McClatchey AI
    Annu Rev Pathol; 2007; 2():191-216. PubMed ID: 18039098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse models of neurofibromatosis 1 and 2.
    Gutmann DH; Giovannini M
    Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic and molecular pathogenesis of NF1 and NF2.
    Yohay KH
    Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis-related tumors: emerging biology and therapies.
    Karajannis MA; Ferner RE
    Curr Opin Pediatr; 2015 Feb; 27(1):26-33. PubMed ID: 25490687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.
    Carroll SL
    Am J Pathol; 2016 Mar; 186(3):464-77. PubMed ID: 26740486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.
    Vasudevan HN; Payne E; Delley CL; John Liu S; Mirchia K; Sale MJ; Lastella S; Nunez MS; Lucas CG; Eaton CD; Casey-Clyde T; Magill ST; Chen WC; Braunstein SE; Perry A; Jacques L; Reddy AT; Pekmezci M; Abate AR; McCormick F; Raleigh DR
    Nat Commun; 2024 Jan; 15(1):477. PubMed ID: 38216572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
    Mashour GA; Ratner N; Khan GA; Wang HL; Martuza RL; Kurtz A
    Oncogene; 2001 Jan; 20(1):97-105. PubMed ID: 11244508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of neurofibromatosis-associated tumours.
    Lin AL; Gutmann DH
    Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurofibromatosis ].
    Wakabayashi T; Saito K; Yoshida J
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():164-9. PubMed ID: 16201518
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurofibromatosis.
    Gerber PA; Antal AS; Neumann NJ; Homey B; Matuschek C; Peiper M; Budach W; Bölke E
    Eur J Med Res; 2009 Mar; 14(3):102-5. PubMed ID: 19380279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurofibromatoses: when less is more.
    Gutmann DH
    Hum Mol Genet; 2001 Apr; 10(7):747-55. PubMed ID: 11257108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.
    Wu M; Wallace MR; Muir D
    J Neurosci Res; 2005 Nov; 82(3):357-67. PubMed ID: 16180234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.
    Ferner RE
    Lancet Neurol; 2007 Apr; 6(4):340-51. PubMed ID: 17362838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
    Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X
    Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibroma and schwannoma.
    Ferner RE; O'Doherty MJ
    Curr Opin Neurol; 2002 Dec; 15(6):679-84. PubMed ID: 12447105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing biologically targeted clinical trials for neurofibromatosis.
    Gutmann DH; Blakeley JO; Korf BR; Packer RJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):443-62. PubMed ID: 23425047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Detection of
    Bianchessi D; Ibba MC; Saletti V; Blasa S; Langella T; Paterra R; Cagnoli GA; Melloni G; Scuvera G; Natacci F; Cesaretti C; Finocchiaro G; Eoli M
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32575496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.